Both retatrutide pens are subcutaneous, multi-dose devices delivering the triple GIP/GLP-1/glucagon receptor agonist in adjustable increments, matching the titration schedule used across the Jastreboff Phase 2 cohort and the ongoing TRIUMPH Phase 3 programme [1] [unverified]
Eloralintide is newer to the research market and carried by far fewer suppliers, which makes documentation the deciding factor rather than price
The study is published in JAMA Psychiatry
The sweet taste signaling system includes heterodimeric G protein-coupled receptors, composed of the taste receptors (TRs), T1R2 + T1R3 heterodimers, which are activated by the binding of sweet compounds such as monosaccharides and disaccharides (126)
The difference is manufacturing location and pricingcompounded tirzepatide is $289/mo month-to-monthnth flat, while Mounjaro typically costs $1,000+ before insurance